Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function

The MESA-RV Study

Steven M. Kawut, R. Graham Barr, W. Craig Johnson, Harjit Chahal, Harikrishna Tandri, Aditya Jain, Michael R. Bristow, Jorge Kizer, Emilia Bagiella, Joao A C Lima, David A. Bluemke

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Elevated resistance and reduced compliance of the pulmonary vasculature increase right ventricular (RV) afterload. Local and systemic inflammation and haemostatic abnormalities are prominent in pulmonary vascular diseases. We hypothesized that plasma biomarker levels indicating greater inflammation and coagulability associated with pulmonary vascular disease would be associated with RV structure and function measured by cardiac magnetic resonance imaging (MRI). The Multi-Ethnic Study of Atherosclerosis (MESA) performed cardiac MRI among participants aged 4584 years without clinical cardiovascular disease. We assessed the associations of RV mass, RV end-diastolic volume (RVEDV), RV stroke volume (RVSV) and RV ejection fraction (RVEF) with plasma measures of inflammation (matrix metalloproteinase (MMP)-3 and -9, intercellular adhesion molecule (ICAM)-1, tumour necrosis factor receptor (TNF-R1), and E-selectin) and thrombosis (plasminogen activator inhibitor (PAI)-1, tissue factor, tissue factor pathway inhibitor and CD40 ligand).The study sample included 731 subjects. Higher MMP-9 levels were associated with lower RV mass before and after adjustment for left ventricular (LV) mass (p0.008 and p0.044, respectively). Higher levels of MMP-9 and PAI-1 were also associated with smaller RVEDV (p<0.05). Higher PAI-1 levels were associated with lower RVEF even after adjustment for LV ejection fraction (p0.017). In conclusion, MMP-9 and PAI-1 are associated with changes in RV structure and function which could be potentially related to a subclinical increase in pulmonary vascular resistance.

Original languageEnglish (US)
Pages (from-to)731-738
Number of pages8
JournalBiomarkers
Volume15
Issue number8
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Right Ventricular Function
Plasminogen Activator Inhibitor 1
Matrix Metalloproteinase 9
Stroke Volume
Atherosclerosis
Magnetic resonance
Inflammation
Vascular Diseases
Lung Diseases
Magnetic Resonance Imaging
Plasmas
Imaging techniques
Matrix Metalloproteinase 3
CD40 Ligand
E-Selectin
Tumor Necrosis Factor Receptors
Thromboplastin
Biomarkers
Hemostatics
Intercellular Adhesion Molecule-1

Keywords

  • Hypertension
  • Inflammation
  • Pulmonary
  • Thrombosis

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function : The MESA-RV Study. / Kawut, Steven M.; Barr, R. Graham; Johnson, W. Craig; Chahal, Harjit; Tandri, Harikrishna; Jain, Aditya; Bristow, Michael R.; Kizer, Jorge; Bagiella, Emilia; Lima, Joao A C; Bluemke, David A.

In: Biomarkers, Vol. 15, No. 8, 12.2010, p. 731-738.

Research output: Contribution to journalArticle

Kawut, SM, Barr, RG, Johnson, WC, Chahal, H, Tandri, H, Jain, A, Bristow, MR, Kizer, J, Bagiella, E, Lima, JAC & Bluemke, DA 2010, 'Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: The MESA-RV Study', Biomarkers, vol. 15, no. 8, pp. 731-738. https://doi.org/10.3109/1354750X.2010.516455
Kawut, Steven M. ; Barr, R. Graham ; Johnson, W. Craig ; Chahal, Harjit ; Tandri, Harikrishna ; Jain, Aditya ; Bristow, Michael R. ; Kizer, Jorge ; Bagiella, Emilia ; Lima, Joao A C ; Bluemke, David A. / Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function : The MESA-RV Study. In: Biomarkers. 2010 ; Vol. 15, No. 8. pp. 731-738.
@article{e680e342c3a94a4db86f04f283ef1186,
title = "Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: The MESA-RV Study",
abstract = "Elevated resistance and reduced compliance of the pulmonary vasculature increase right ventricular (RV) afterload. Local and systemic inflammation and haemostatic abnormalities are prominent in pulmonary vascular diseases. We hypothesized that plasma biomarker levels indicating greater inflammation and coagulability associated with pulmonary vascular disease would be associated with RV structure and function measured by cardiac magnetic resonance imaging (MRI). The Multi-Ethnic Study of Atherosclerosis (MESA) performed cardiac MRI among participants aged 4584 years without clinical cardiovascular disease. We assessed the associations of RV mass, RV end-diastolic volume (RVEDV), RV stroke volume (RVSV) and RV ejection fraction (RVEF) with plasma measures of inflammation (matrix metalloproteinase (MMP)-3 and -9, intercellular adhesion molecule (ICAM)-1, tumour necrosis factor receptor (TNF-R1), and E-selectin) and thrombosis (plasminogen activator inhibitor (PAI)-1, tissue factor, tissue factor pathway inhibitor and CD40 ligand).The study sample included 731 subjects. Higher MMP-9 levels were associated with lower RV mass before and after adjustment for left ventricular (LV) mass (p0.008 and p0.044, respectively). Higher levels of MMP-9 and PAI-1 were also associated with smaller RVEDV (p<0.05). Higher PAI-1 levels were associated with lower RVEF even after adjustment for LV ejection fraction (p0.017). In conclusion, MMP-9 and PAI-1 are associated with changes in RV structure and function which could be potentially related to a subclinical increase in pulmonary vascular resistance.",
keywords = "Hypertension, Inflammation, Pulmonary, Thrombosis",
author = "Kawut, {Steven M.} and Barr, {R. Graham} and Johnson, {W. Craig} and Harjit Chahal and Harikrishna Tandri and Aditya Jain and Bristow, {Michael R.} and Jorge Kizer and Emilia Bagiella and Lima, {Joao A C} and Bluemke, {David A.}",
year = "2010",
month = "12",
doi = "10.3109/1354750X.2010.516455",
language = "English (US)",
volume = "15",
pages = "731--738",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function

T2 - The MESA-RV Study

AU - Kawut, Steven M.

AU - Barr, R. Graham

AU - Johnson, W. Craig

AU - Chahal, Harjit

AU - Tandri, Harikrishna

AU - Jain, Aditya

AU - Bristow, Michael R.

AU - Kizer, Jorge

AU - Bagiella, Emilia

AU - Lima, Joao A C

AU - Bluemke, David A.

PY - 2010/12

Y1 - 2010/12

N2 - Elevated resistance and reduced compliance of the pulmonary vasculature increase right ventricular (RV) afterload. Local and systemic inflammation and haemostatic abnormalities are prominent in pulmonary vascular diseases. We hypothesized that plasma biomarker levels indicating greater inflammation and coagulability associated with pulmonary vascular disease would be associated with RV structure and function measured by cardiac magnetic resonance imaging (MRI). The Multi-Ethnic Study of Atherosclerosis (MESA) performed cardiac MRI among participants aged 4584 years without clinical cardiovascular disease. We assessed the associations of RV mass, RV end-diastolic volume (RVEDV), RV stroke volume (RVSV) and RV ejection fraction (RVEF) with plasma measures of inflammation (matrix metalloproteinase (MMP)-3 and -9, intercellular adhesion molecule (ICAM)-1, tumour necrosis factor receptor (TNF-R1), and E-selectin) and thrombosis (plasminogen activator inhibitor (PAI)-1, tissue factor, tissue factor pathway inhibitor and CD40 ligand).The study sample included 731 subjects. Higher MMP-9 levels were associated with lower RV mass before and after adjustment for left ventricular (LV) mass (p0.008 and p0.044, respectively). Higher levels of MMP-9 and PAI-1 were also associated with smaller RVEDV (p<0.05). Higher PAI-1 levels were associated with lower RVEF even after adjustment for LV ejection fraction (p0.017). In conclusion, MMP-9 and PAI-1 are associated with changes in RV structure and function which could be potentially related to a subclinical increase in pulmonary vascular resistance.

AB - Elevated resistance and reduced compliance of the pulmonary vasculature increase right ventricular (RV) afterload. Local and systemic inflammation and haemostatic abnormalities are prominent in pulmonary vascular diseases. We hypothesized that plasma biomarker levels indicating greater inflammation and coagulability associated with pulmonary vascular disease would be associated with RV structure and function measured by cardiac magnetic resonance imaging (MRI). The Multi-Ethnic Study of Atherosclerosis (MESA) performed cardiac MRI among participants aged 4584 years without clinical cardiovascular disease. We assessed the associations of RV mass, RV end-diastolic volume (RVEDV), RV stroke volume (RVSV) and RV ejection fraction (RVEF) with plasma measures of inflammation (matrix metalloproteinase (MMP)-3 and -9, intercellular adhesion molecule (ICAM)-1, tumour necrosis factor receptor (TNF-R1), and E-selectin) and thrombosis (plasminogen activator inhibitor (PAI)-1, tissue factor, tissue factor pathway inhibitor and CD40 ligand).The study sample included 731 subjects. Higher MMP-9 levels were associated with lower RV mass before and after adjustment for left ventricular (LV) mass (p0.008 and p0.044, respectively). Higher levels of MMP-9 and PAI-1 were also associated with smaller RVEDV (p<0.05). Higher PAI-1 levels were associated with lower RVEF even after adjustment for LV ejection fraction (p0.017). In conclusion, MMP-9 and PAI-1 are associated with changes in RV structure and function which could be potentially related to a subclinical increase in pulmonary vascular resistance.

KW - Hypertension

KW - Inflammation

KW - Pulmonary

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=78649309274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649309274&partnerID=8YFLogxK

U2 - 10.3109/1354750X.2010.516455

DO - 10.3109/1354750X.2010.516455

M3 - Article

VL - 15

SP - 731

EP - 738

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 8

ER -